A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase.
A study conducted in Canada to estimate the prevalence of psychotropic and opioid medication use by older women diagnosed with breast cancer found a significant increase in use, especially during the active treatment phase. Antidepressant use, on the other hand, persisted through active treatment and into survivorship.
Breast cancer diagnosis is more common in older women, who usually present with comorbidities and associated polypharmacy. Further, age-related cognitive decline and greater susceptibility to adverse reactions from cancer-related treatments could be a source of anxiety and distress in this patient population. To complicate matters, studies have shown that antidepressant medications could interfere with the efficacy of breast cancer treatments like tamoxifen. With this in mind, the authors conducted the present study, the results of which have been published in the Journal of the National Comprehensive Cancer Network, to understand pharmacologic management of distress and pain in this high-risk group of patients.
The study followed 19,353 women over age 65 who were diagnosed with incident, nonmetastatic breast cancer in Quebec, Canada. Health data were sourced from provincial, universal health, and drug insurance plans. Psychotropic and opioid medication use was assessed across the care trajectory, from the precancer stage until the first year of survivorship.
A significant increase in medication use was observed from the precancer stage into active treatment, followed by a drop in use during the first year of survivorship. Anxiolytics, the authors write, were more commonly used across the care trajectory by the studied patient population—36.3% at baseline, 50.6% during active treatment, and 44.4% during survivorship. Antipsychotic and opioid medications saw a spike in utilization during the active treatment phase: a 4.5- and 7-fold increase compared with baseline. Antidepressant use, however, peaked during the active phase (22.4%, up from 14.7% at baseline) and then was sustained during survivorship (22.3%).
Accounting for the fact that these older women who were receiving treatment for their cancer experienced distress and pain across their care trajectory, and the risk of drug-drug interactions leading to adverse events, the authors recommend integrating psychological interventions in the treatment plan to address these women’s needs.
Reference
Syrowatka A, Chang SL, Tamblyn R, Mayo NE, Meguerditchian AN. Psychotropic and opioid medication use in older patients with breast cancer across the care trajectory: a population-based cohort study. J Natl Compr Canc Netw. 2016;14(11):1412-1419.
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
Real-World Study Reveals Key Insights into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More
Low-Volume Hospitals Had Higher Reoperation Rate, Postoperative Complications in CRC
April 18th 2024Patients opting for elective colorectal surgery to address colorectal cancer (CRC) could have different rates of reoperation and postoperative complications based on the size of the hospital.
Read More
2 Commerce Drive
Cranbury, NJ 08512